---
title: Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia
  Vera
date: '2024-02-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38381675/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240222170755&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSIONS: In patients with polycythemia vera, rusfertide treatment
  was associated with a mean hematocrit of less than 45% during the 28-week dose-finding
  period, and the percentage of patients with a response during the 12-week randomized
  withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist
  Therapeutics; REVIVE ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with polycythemia vera, rusfertide treatment was associated with a mean hematocrit of less than 45% during the 28-week dose-finding period, and the percentage of patients with a response during the 12-week randomized withdrawal period was greater with rusfertide than with placebo. (Funded by Protagonist Therapeutics; REVIVE ClinicalTrials.gov number, ...